Antibiotic Development: Where Wall Street Guidance Is Watching FDA Guidances

FDA’s effort to create a clearer path for antibiotic development has produced a series of new guidance documents. Those guidances are making some products in development look well-positioned for regulatory review, and rekindling the interest on Wall Street in specialty antibiotic firms.

By Laura Helbling

Trius Therapeutics is carrying an interesting new message to investors: the antibiotic approval criteria have changed at the Food &...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet